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Abstract
Introduction Bisphosphonates have become standard therapy
for the treatment of skeletal complications related to breast
cancer. Although their therapeutic effects mainly result from an
inhibition of osteoclastic bone resorption, in vitro data indicate
that they also act directly on breast cancer cells, inhibiting
proliferation and inducing apoptosis.
Methods The present study examined the effects of calcium
(from 0.6 to 2.0 mmol/l) on the antitumour activity of the
bisphosphonate ibandronate (1 to 1,000 nmol/l) on MDA-MB-
231 and MCF-7 breast cancer cells. Cell culture densities were
determined using crystal violet staining assay. Apoptotic cell
death was assessed by annexin V-phycoerythrin and 7-amino-
actinomycin double staining.
Results At low calcium concentration, 30 μmol/l ibandronate
had no effect on MDA-MB-231 cells growth and only slightly
inhibited MCF-7 cells growth. Higher calcium levels significantly
increased growth inhibition as well as cell apoptosis induced by
ibandronate. We observed similar effects with zoledronic acid.
Of note, enhancement of ibandronate-induced growth inhibition
was also observed in other breast cancer cell lines (T-47D, ZR-
75, Hs-578T and BT-549 cells). The growth inhibitory effect of
ibandronate in the presence of high concentrations of calcium
was partly suppressed by the calcium chelator EGTA (ethylene
glycol tetra-acetic acid). In addition, in the presence of calcium
at high concentrations, cells accumulated more
[14C]ibandronate than at low calcium concentrations. We
obtained further evidence of enhancement of cellular
ibandronate accumulation by calcium by demonstrating that
high calcium levels increased the inhibition of protein prenylation
induced by the bisphosphonate.
Conclusion Altogether, our data suggest that extracellular
calcium, probably through its binding to ibandronate, markedly
increased its cellular accumulation and its inhibitory activity on
breast tumour cells. Thus, calcium released during the process
of tumour-induced osteolysis might enhance the antitumour
effects of bisphosphonates and contribute to their therapeutic
efficacy.
Introduction
Breast carcinoma is the most frequent malignancy occurring in
women of Western developed countries. The skeleton is the
commonest site for metastasis of breast cancer. Bone metas-
tases represent a major public health concern because of their
frequency and the severe morbidity that they generate in can-
cer patients (hypercalcaemia, severe pain, pathological frac-
tures and so on) [1].
Bisphosphonates are used as the standard therapy for hyper-
calcaemia complicating breast cancer and they are now com-
monly administered for the treatment of bone metastases.
These potent agents inhibit the activity of osteoclasts and
induce their apoptosis [2]. In addition to their effects of bone
cells, recent in vitro and animal studies have shown that the
bisphosphonates also directly inhibit the proliferation and
induce the apoptosis of osteotropic cancer cells [3-8]. By
inhibiting osteoclast-mediated bone resorption, they can also
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interrupt the vicious circle between tumour cells, osteoclasts
and bone matrix, thereby limiting the release of growth factors.
Moreover, they can directly inhibit the mitogenic effect of
growth factors on cancer cells [9].
Bisphosphonates are nonhydrolyzable analogues of pyrophos-
phate. They are effective chelators of calcium [10], they have
high affinity for the bone tissue and they preferentially accumu-
late at sites of active bone remodelling [11]. Previous data
[12] indicated that a fluorescent analogue of bisphosphonate
is rapidly internalized into intracellular vesicles in osteoclasts.
Fluid-phase endocytosis is involved in the initial internalization
of bisphosphonates into vesicles, and endosomal acidification
is then required for the exit of bisphosphonate from vesicles
and entry into cytosol.
There are two classes of bisphoshonates that differ with
regard to structure and mechanism of action [13]. The first one
includes pyrophosphate-resembling bisphosphonates, such
as clodronate and etidronate, which are metabolically incorpo-
rated into nonhydrolyzable ATP analogues that act as inhibi-
tors of ATP-dependent enzymes [14]. The second class is
more recent and includes nitrogen-containing bisphospho-
nates, such as alendronate, pamidronate, risedronate, ibandr-
onate and zoledronic acid, which interfere with the mevalonate
pathway, inhibiting the farnesyl diphosphate synthase and
blocking the farnesylation and the geranylgeranylation of small
GTPase proteins [15]. In the case of nitrogen-containing
bisphosphonates, inhibition of protein prenylation is probably
the main mechanism of action that leads to cytotoxic effects,
even though additional mechanisms have been advanced
[16]. In particular, a previous study [17] reported that alendro-
nate increased intracellular calcium concentration in osteo-
clasts. Under some circumstances, an increase in intracellular
calcium level may cause cell death by necrosis or apoptosis
[18].
The skeleton is a repository for mineral, especially calcium.
Consequently, tumour-induced bone resorption leads to the
release of large quantities of calcium into the bone microenvi-
ronment. Interestingly, the local calcium level at resorption
sites has been reported to rise as high as 40 mmol/l [19].
Hence, metastatic breast cancer cells near resorbing osteo-
clasts are likely to be exposed to 'hypercalcaemic' conditions
(2.0 mmol/l), which may influence therapeutic efficacy.
In spite of considerable therapeutic progress achieved with
the use of bisphosphonates, the current treatment protocols
reduce bone morbidity by 'only' 40% to 50%, suggesting that
these drugs block tumour-induced osteolysis only partially
[20]. A better understanding of the mechanisms of action of
bisphosphonates on tumour cells would make it possible to
use them more efficiently and to improve clinical results. In the
present study we examined the effects of an increase in extra-
cellular calcium level (0.6 to 2.0 mmol/l) on the antitumour
activity of ibandronate in MDA-MB-231 and MCF-7 breast
cancer cell lines.
Materials and methods
Breast cancer cell lines and culture conditions
The MCF-7 (HTB-22), MDA-MB-231 (HTB-26), T-47D (HTB-
133), ZR-75-1 (CRL-1500), Hs 578T (HTB-126) and BT-549
(HTB-122) breast cancer cell lines were obtained from the
American Type Culture Collection (Manassas, VA, USA). Cells
were cultured at 37°C in a humidified 95% air and 5% carbon
dioxide atmosphere. For routine maintenance, cells were prop-
agated in 75 cm2 flasks containing complete RPMI medium
consisting of RPMI 1640 with phenol red, supplemented with
5% heat-inactivated foetal bovine serum and with L-glutamine,
penicillin and streptomycin at standard concentrations (all
from Gibco BRL, Life Technologies, Merelbeke, Belgium).
Cells were harvested by trypsinization (0.1% trypsin, 0.02%
EDTA) and subcultured twice weekly.
For experiments, cells were plated in complete RPMI medium.
One day after seeding, the culture medium was replaced by
fresh medium adjusted to the final desired calcium concentra-
tions (from 0.6 to 2.0 mmol/l) by adding CaCl2.2H2O (Sigma,
St Louis, MO, USA) along with contain drugs and/or other
chemicals. Of note, standard RPMI medium contains 0.6
mmol/l calcium, as calculated from the manufacturer's data.
Ibandronate and [14C]ibandronate (102 mCi/mmol) were sup-
plied by Roche Diagnosics GmbH (Penzberg, Germany) and
F. Hoffmann-La Roche Ltd (Basel, Switzerland), respectively.
Zoledronic acid was supplied by Novartis (Basel, Switzerland).
Paclitaxel, ethylene glycol tetra-acetic acid (EGTA) and MgCl2
were from Sigma. Calcium-sensing receptor (CaR) agonist
(NPS R-467) and antagonist were kindly provided by Dr J Fox
(NPS Pharmaceuticals, Salt Lake City, UT, USA). Cells were
treated for 1 to 72 hours, as specified in Results (see below).
Cell growth assay
Cell number was assessed indirectly by staining with crystal
violet dye, as described in a previous report [21]. Briefly, cells
were seeded in 96-well plates at a density of 2,500 cells/well
in complete RPMI medium and cultured for 24 hours. Cells
were then exposed for 72 hours or less (pulse exposures) to
calcium, drugs and other compound(s) alone or in combina-
tion, as described in Results (see below). Medium was
removed, cells were gently rinsed with phosphate-buffered
saline (PBS), fixed with 1% glutaraldehyde/PBS for 15 min-
utes and stained with 0.1% crystal violet (weight/vol in double
distilled H2O) for 30 minutes. Cells were destained under run-
ning tap water for 15 minutes and subsequently lysed with
0.2% Triton X-100 (vol/vol in double distilled H2O). The
absorbance was measured at 550 nm using a Microplate
Autoreader EL309 (BIO-TEK Instruments, Winooski, VT,
USA). Blank wells containing medium alone were used for
background subtraction and sham-treated cells were cultured
in parallel as controls.Available online http://breast-cancer-research.com/content/10/1/R4
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Apoptosis determination
Apoptotic cell death was assessed using annexin V-phyco-
erythrin (PE) apoptosis detection kit I (BD Pharmingen, Erem-
bodegem, Belgium), in accordance with the manufacturer's
recommendations. Briefly, cells were seeded in six-well plates
(density 50,000 cells/well), cultured for 24 hours and treated
with bisphosphonates in presence or absence of additional
calcium concentrations for 72 hours, as described in Results
(see below). Cell monolayers were washed twice in PBS, har-
vested by trypsinization, centrifuged and resuspended in 100
μl 1× Binding Buffer (BD Pharmingen). After addition of 5 μl
annexin V-PE and 5 μl of 7-amino-actinomycin (7-AAD, a vital
dye), cell suspensions were incubated for 15 minutes at room
temperature in darkness. Finally, cell samples were diluted
with 400 μl 1× binding buffer and analyzed in a flow cytometer
(FACSCalibur, Becton Dickinson, Franklin Lakes, NJ, USA)
within 1 hour. Data are presented as percentages of annexin
V-PE positive and 7-AAD negative cells.
Western blot analysis
Unprenylated Rap1A and total Rap1 were determined by
Western blotting. Cells were plated at a density of 104 cells/
cm2 in 60 cm2 Petri dishes containing complete RPMI medium,
cultured for 24 hours and then incubated for 24 additional
hours with calcium (0.6 or 2.0 mmol/l) and ibandronate (1 to
1,000 μmol/l) or vehicle as specified in Results (see below).
Cell monolayers were rinsed twice with Tris-buffered saline
(50 mmol/l Tris-HCl [pH 7.5], 150 mmol/l NaCl), lysed in Tris-
buffered saline containing 0.5% sodium deoxycholate, 1%
Nonidet P-40, 0.1% SDS, 50 mmol/l NaF, 0.1 mM Na3VO4
and 5 mmol/l EDTA with freshly added proteolysis inhibitors,
and finally centrifuged. Protein concentrations in cell lysate
supernatants were determined by the BCA Protein Assay
(Pierce, Rockford, IL, USA) using bovine serum albumin as
standard. Equal amounts of protein were subjected to West-
ern blotting using a goat polyclonal anti-human Rap1A anti-
body (SC-1482; Santa Cruz Biotechnology, Santa Cruz, CA,
USA) diluted 1:1,000, which recognizes the unprenylated
form of the small GTPase Rap1A [22], and a rabbit polyclonal
anti-human Rap1 antibody (SC-65; Santa Cruz Biotechnol-
ogy) diluted 1:500. Peroxidase-labelled anti-goat IgG antibody
(1:1,500; Pierce) and peroxidase-labelled anti-rabbit IgG anti-
body (1:2,500; Amersham Pharmacia Biotech, Roosendaal,
The Netherlands) were used as secondary reagents to detect
corresponding primary antibodies. Bound peroxidase activity
was revealed using the SuperSignal® West Pico Chemilumi-
nescent Substrate (Pierce). Immunostaining signals were digi-
talized with a PC-driven LAS-3000 CCD camera (Fujifilm,
Tokyo, Japan), using software specifically designed for image
acquisition (Image Reader, Raytest®, Straubenhardt,
Germany).
Measurement of [14C]ibandronate accumulation in cells
Bisphosphonate accumulation by breast cancer cells was
determined by using [14C]ibandronate. Cells were seeded in
12-well plates at a density of 40,000 cells/well in complete
RPMI medium and cultured for 24 hours. Cells were then incu-
bated in fresh medium supplemented or not supplemented
with calcium and containing 10 μmol/l [14C]ibandronate (102
mCi/mmol) for 4 hours, as described in Results (seee below).
Cell monolayers were rinsed and lysed as described under
Western blot analysis (see above). The amounts of [14C]iban-
dronate associated with cell lysate supernatants were deter-
mined using a liquid scintillation counter (Wallac 1409;
PerkinElmer, Waltham, MA, USA). Protein concentrations in
the same samples were measured by the BCA Protein Assay
(Pierce), using bovine serum albumin as standard. Results
were expressed as picomoles of ibandronate per milligram of
protein.
Statistical analysis
Data are reported as means ± standard deviation, and statisti-
cal analysis was performed by analysis of variance. Dunnett
post hoc test was used to compare treated conditions with the
untreated condition (control), and Tukey post hoc test was
performed for multiple comparisons between groups. The
level of statistical significance was arbitrarily set at 0.01. All
analyses were conducted using SPSS software (SPSS Inc.,
Paris, France).
Results
High extracellular calcium concentration increases 
ibandronate-induced cell growth inhibition and cell 
apoptosis
Breast cancer cells were cultured in complete RPMI medium
containing 5% foetal bovine serum and supplemented or not
supplemented with CaCl2, to achieve calcium concentrations
from 0.6 to 2.0 mmol/l. Cell growth was assessed after 72
hours of treatment with ibandronate.
In the presence of 0.6 mmol/l calcium, 30 μmol/l ibandronate
had no effect on MDA-MB-231 cell growth, whereas it slightly
inhibited MCF-7 cell growth by 13.6 ± 6.6% (Figure 1). Higher
extracellular calcium concentrations enhanced the inhibitory
effects of ibandronate in a dose-dependent manner. Indeed, in
the presence of 2.0 mmol/l calcium, 30 μmol/l ibandronate
dramatically inhibited cell proliferation by 55.5 ± 7.8% and
76.1 ± 4.6% (P < 0.01) in MDA-MB-231 and MCF-7 cells,
respectively. Half maximal inhibitory concentration (IC50) val-
ues for growth inhibition by ibandronate were determined in
presence of 0.6 and 1.6 mmol/l calcium. Dose-response
curves revealed that an increase in calcium concentration
decreased the IC50 values of ibandronate from 150 to 60
μmol/l in MDA-MB-231 cells and from 80 to 10 μmol/l in MCF-
7 cells (Figure 2 and Table 1). Similar effects were also docu-
mented in four additional breast cancer cell lines (T-47D, ZR-
75-1, Hs-578T and BT-549; Table 1), indicating that these
observations are not restricted to particular cell lines. Of note,
a higher sensitivity of tumour cells to ibandronate appeared to
be associated with the oestrogen receptor (ER) status, butBreast Cancer Research    Vol 10 No 1    Journé et al.
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appeared to be independent of the type of bone lesions that
the tumour cells may develop in nude mice. Altogether, these
data indicated that high calcium concentration enhanced the
growth inhibitory potency of ibandronate in breast cancer
cells.
Annexin V-PE labelling was used to detect apoptotic cell
death. Cell apoptosis rates were low (<3% in both cell lines)
in the control condition (0.6 mmol/l calcium) and did not sig-
nificantly change in presence of 1.6 mmol/l calcium (Figure 3).
Ibandronate (30 μmol/l) did not induce significant cell apopto-
sis in presence of 0.6 mmol/l calcium. By contrast, it signifi-
cantly increased the percentage of annexin V-PE-positive cells
in the presence of 1.6 mmol/l calcium (11.4% and 32.9% in
MDA-MB-231 and MCF-7 cells, respectively; Figure 3). Simi-
lar observations were obtained with zoledronic acid, except
that the latter drug provoked more extensive apoptosis, partic-
ularly in presence of 1.6 mmol/l calcium (17% and 52% for
MDA-MB-231 and MCF-7 cells, respectively).
As documented above by analyzing bisphosphonate-induced
apoptosis, the modulating effect of calcium was not restricted
to ibandronate, because this cation also increased the growth
inhibition produced by zoledronic acid (Figure 4a). Thus, dose-
response curves showed that an increase in calcium level from
0.6 to 1.6 mmol/l diminished the IC50 values of zoledronic acid
from 50 to 15 μmol/l in MDA-MB-231 cells and from 20 to 2
μmol/l in MCF-7 cells. Interestingly, these effects were spe-
cific to bisphosphonates because calcium had no effect on the
cytotoxicity induced by the structurally unrelated antimitotic
agent paclitaxel (Figure 4b). In addition, the enhancement of
ibandronate activity was specifically noted with calcium, inas-
much as it was not observed with the other divalent cation
magnesium in the same range of concentrations (Figure 4c).
On the other hand, calcium chelation by EGTA at 0.5 mmol/l,
a concentration that did not affect cell growth, significantly
reduced the growth inhibitory effect induced by 30 μmol/l
ibandronate in culture medium containing 1.6 mmol/l calcium
(Figure 5). Similarly, calcium chelation by 100 μmol/l clodro-
Figure 1
Effect of calcium on the growth inhibition induced by ibandronate in  MDA-MB-231 and MCF-7 cells Effect of calcium on the growth inhibition induced by ibandronate in 
MDA-MB-231 and MCF-7 cells. Cells were treated for 72 hours with 
30 μmol/l ibandronate (open circles) in the presence of increasing con-
centrations of calcium (0.6 to 2.0 mmol/l; filled circles, no ibandronate). 
Cell culture densities were determined by crystal violet staining assay. 
Data are expressed as percentages (mean ± standard deviation) of 
control values, which refer to cultures in presence of 0.6 mmol/l cal-
cium and without ibandronate. Mean of results pooled from three exper-
iments (n = 18). *P < 0.01 versus no ibandronate, analysis of variance, 
Tukey post hoc test.
Figure 2
Concentration-effect relationships of ibandronate on cancer cell prolif- eration in hypocalcaemic or hypercalcaemic conditions Concentration-effect relationships of ibandronate on cancer cell prolif-
eration in hypocalcaemic or hypercalcaemic conditions. MDA-MB-231 
and MCF-7 cells were exposed for 72 hours to increasing ibandronate 
concentrations (1 to 1,000 μmol/l) in culture medium containing 0.6 
mmol/l calcium (filled squares) or 1.6 mmol/l calcium (open squares). 
Cell culture densities were evaluated by crystal violet staining assay. 
Data are presented as percentages (mean ± standard deviation) of 
control values, which refer to cultures with 0.6 mmol/l calcium and with-
out ibandronate. Mean of results pooled from three experiments (n = 
18). *P < 0.01 versus 0.6 mmol/l calcium, analysis of variance, Tukey 
post hoc test.Available online http://breast-cancer-research.com/content/10/1/R4
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nate, a pyrophosphate-resembling bisphosphonate that had
no detectable effect on cell survival at this concentration, sig-
nificantly reversed the growth inhibition induced by ibandro-
nate (data not shown).
Calcium-sensing receptor is not involved in the effect of 
calcium on ibandronate-induced cell growth inhibition
A potential role of the CaR in mediating the effects of calcium
on cell growth inhibition induced by ibandronate was checked
by using CaR regulators. The CaR agonist NPS R-467 at 10-
5 mol/l did not mimic the effects of high extracellular calcium
concentrations, because it did not enhance growth inhibition
by ibandronate (Figure 6). Likewise, the CaR antagonist at 10-
6 mol/l did not change the growth inhibitory effect of ibandro-
nate at 1.6 mmol/l calcium concentration. Therefore, these
data excluded the possibility that CaR might be involved in the
modulation of bisphosphonate effect by calcium.
Table 1
Comparison of the effect of ibandronate on six breast cancer cell lines
IC50 (μmol/l)
Cell line ER statusa Bone lesionsb 0.6 mmol/l calcium 1.6 mmol/l calcium
T-47D + Blastic 35c 2
ZR-75-1 + Lytic 50 15
MCF-7 + Blastic 80 10
Hs-578T - Blastic 100 10
BT-549 - Lytic 150 10
MDA-MB-231 - Lytic 150 60
aAs described by American Type Culture Collection (Manassas, VA, USA). bAs defined by Yin and coworkers [32] and Lacroix and colleagues 
[33]. cHalf maximal inhibitory concentration (IC50) values determined from concentration-effect curves for cancer cells exposed for 72 hours to 
ibandronate (1 to 1,000 μmol/l) in the presence of 0.6 or 1.6 mmol/l calcium. Cell culture densities were evaluated by crystal violet staining assay. 
Means of results pooled from three experiments (n = 18). ER, oestrogen receptor.
Figure 3
Effect of calcium on cell apoptosis induced by bisphosphonates in MDA-MB-231 and MCF-7 cells Effect of calcium on cell apoptosis induced by bisphosphonates in MDA-MB-231 and MCF-7 cells. Cells were incubated for 72 hours with 30 μmol/
l ibandronate (Iban) or zoledronic acid (Zole) in culture medium containing 0.6 or 1.6 mmol/l calcium. Apoptotic cell death was assessed by annexin 
V-phycoerythrin (PE) and 7-amino-actinomycin (7-AAD) double staining. Data are presented as percentages (mean ± standard deviation) of annexin 
V-PE-positive (AN+) and 7-AAD-negative cells. Mean of results pooled from two experiments (n = 4). *P < 0.01 versus 0.6 mmol/l calcium, analysis 
of variance, Tukey post hoc test.Breast Cancer Research    Vol 10 No 1    Journé et al.
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High extracellular calcium concentration enhances 
[14C]ibandronate accumulation in breast carcinoma cells 
and increases ibandronate effect on prenylation
In order to address the effects of calcium on cellular accumu-
lation of ibandronate, MDA-MB-231 and MCF-7 cells were
cultured in medium containing 0.6 or 2.0 mmol/l calcium and
were exposed to 10 μmol/l [14C]ibandronate for 4 hours (Fig-
ure 7). In the presence of 2.0 mmol/l calcium, cells accumu-
lated more radiolabelled ibandronate than cells cultured in
presence of 0.6 mmol/l calcium (about 4.6-fold and 11.4-fold
increases in MDA-MB-231 and MCF-7 cells, respectively).
Interestingly, MCF-7 cells accumulated threefold more
Figure 4
Comparative study of calcium effect on zoledronic acid or paclitaxel, and magnesium effect on ibandronate Comparative study of calcium effect on zoledronic acid or paclitaxel, and magnesium effect on ibandronate. Cells were exposed for (a) 72 hours to 
increasing concentrations of zoledronic acid (1 to 1,000 μmol/l) or (b) to increasing concentrations of paclitaxel (0.1 to 1,000 μmol/l), in culture 
medium containing 0.6 mmol/l calcium (filled squares) or 1.6 mmol/l calcium (open squares), or (c) to 30 μmol/l ibandronate (open circles) in the 
presence of increasing magnesium concentrations (0.4 to 1.8 mmol/l; filled circles, no ibandronate). Cell culture densities were measured by crystal 
violet staining assay. Data are presented as percentages (mean ± standard deviation) of control values, which refer to culture with 0.6 mmol/l cal-
cium or 0.4 mmol/l magnesium and without drug. Mean of results pooled from two experiments (n = 12).Available online http://breast-cancer-research.com/content/10/1/R4
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[14C]ibandronate than did MDA-MB-231 cells, which could
contribute to the higher sensitivity of the former cells to
bisphosphonates (Figure 1 to 3).
Recent data indicate that nitrogen-containing bisphospho-
nates induce a dose-dependent accumulation of unprenylated
Rap1A in MDA-MB-231 cells [23]. We confirmed that
calcium-induced modulation of cellular accumulation of iband-
ronate took place by demonstrating that high calcium concen-
tration augmented ibandronate-induced inhibition of protein
prenylation (Figure 8). Indeed, in both cell lines 10 μmol/l iban-
dronate was sufficient to produce a detectable inhibition of
Rap1A prenylation in the presence of 2.0 mmol/l calcium,
whereas 100 μmol/l ibandronate was required to achieve a
similar effect in presence of 0.6 mmol/l calcium. Therefore,
high calcium level increased the intracellular activity of ibandr-
onate, probably by favouring cellular drug accumulation.
High extracellular calcium concentration decreases the 
treatment duration required to obtain an effective 
ibandronate-induced cell growth inhibition
Figure 9 illustrates the growth inhibitory effect of shorter expo-
sures (1 and 6 hours) to ibandronate plus calcium at low or
high concentrations. In culture medium containing 0.6 mmol/l
calcium, 1 hour of ibandronate treatment had no or only a weak
effect on breast cancer cell growth. As expected, continuous
treatment (72 hours) increased bisphosphonate-induced
inhibition of growth. In the presence of 1.6 mmol/l calcium,
exposure to ibandronate for 1 hour dramatically decreased cell
proliferation. Moreover, in these experimental conditions,
inhibition of cell growth was more effective than after 72 hours
of ibandronate treatment with low calcium concentration. Of
note, 6 hours of exposure produced intermediate effects.
These data brought further evidence that calcium enhances
the growth inhibitory effect of ibandronate in breast cancer
cells, even in the case of short treatment durations, suggesting
a significant decrease in the time needed to obtain an effective
cell accumulation of the bisphosphonate.
Discussion
Metastatic bone disease is the main cause of morbidity in
breast cancer patients [1]. Tumour-induced osteolysis pro-
vokes an excessive and uncontrolled release of calcium from
the bone matrix, notably resulting in malignant hypercalcaemia.
As a matter of fact, metastastic breast cancer cells proliferate
in bone tissue microenvironment, and high calcium concentra-
tion can influence the activity of therapeutic agents aimed at
treating bone metastases.
Bisphosphonates are currently used to alleviate tumour-asso-
ciated bone diseases [20]. They have high affinity for calcium
and accumulate in bone tissue, where they are efficiently taken
up by bone-resorbing osteoclasts. On the other hand, nonre-
sorbing cells such as tumour cells have a lesser tendency to
accumulate bisphosphonates and therefore are likely to exhibit
less sensitivity to these drugs [24].
In the present study, we documented the effect of ibandronate
and zoledronic acid on the proliferation and the apoptosis of
MDA-MB-231 and MCF-7 cells in the presence of various clin-
ically relevant extracellular calcium concentrations (0.6 to 2.0
mmol/l). Our data show that high calcium level strongly
increases the growth inhibitory effects of ibandronate and
zoledronic acid in both cell lines. Moreover, these observations
were not restricted to MDA-MB-231 and MCF-7 cells,
because they could be extended to four other breast cancer
cell lines (T-47D, ZR-75-1, Hs-578T and BT-549). Thus, the
antitumour activity of bisphosphonates appears to be calcium
dependent. By contrast, the cytotoxicity of the chemothera-
peutic agent paclitaxel is independent of extracellular calcium.
It can be inferred from these observations that calcium does
not simply act by modulating cell drug sensitivity in a nonspe-
cific manner. The chelator EGTA abrogates the influence of
Figure 5
Effect of EGTA on growth inhibition induced by ibandronate in pres- ence of high calcium concentration Effect of EGTA on growth inhibition induced by ibandronate in pres-
ence of high calcium concentration. MDA-MB-231 and MCF-7 cells 
were treated for 72 hours with 30 μmol/l ibandronate (Iban) alone or 
with 500 μmol/l ethylene glycol tetra-acetic acid (EGTA) in culture 
medium containing 1.6 mmol/l calcium. Cell culture densities were 
determined by crystal violet staining assay. Data are presented as per-
centages (mean ± standard deviation) of control values, which refer to 
culture with 1.6 mmol/l calcium and without drugs. Mean of results 
pooled from two experiments (n = 12). *P < 0.01 between indicated 
conditions, analysis of variance; #P < 0.01 versus control, analysis of 
variance; Tukey post hoc test.Breast Cancer Research    Vol 10 No 1    Journé et al.
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calcium on ibandronate-induced growth inhibition, probably by
competing with the bisphosphonate for calcium complexation.
Because the phosphonate groups allow effective chelation of
metal ions [25], it may be speculated that the increase in extra-
cellular complexation favours the emergence of bisphospho-
nate-calcium complexes, leading to changed drug
pharmacokinetics at the cellular level and to a rapid enhance-
ment of drug accumulation in tumour cells. The validity of this
interpretation is confirmed by the fact that an augmentation of
extracellular calcium increases the cellular accumulation of
[14C]ibandronate, accentuates ibandronate-induced inhibition
of Rap1A prenylation, and leads to effective antitumour effects
of ibandronate after exposure duration of as short as 1 hour.
It is worth noting that an enhancing effect of calcium on cellu-
lar bisphosphonate accumulation and on drug activity has
been demonstrated in other cell types. Indeed, a previous
study showed that high extracellular calcium concentration
enhances the growth inhibitory action of bisphosphonates on
RAW264 macrophage-like cells [26], suggesting that the
uptake of bisphosphonates by macrophages is favoured by
calcium. Moreover, another study revealed that bisphospho-
nates are more toxic to the Caco-2 intestinal cancer cell line in
the presence of calcium than in the absence of calcium [27].
As reported recently, the pyrophosphate-resembling clodro-
nate acts as a calcium chelator and inhibits cell uptake of
radiolabelled ibandronate in macrophages and osteoclasts
[28]. In addition, the uptake of [14C]zoledronic acid or of a flu-
orescent analogue of alendronate by J774 macrophages and
rabbit osteoclasts is enhanced by the presence of calcium and
strontium, and is inhibited by addition of EGTA or clodronate
[12]. That study also revealed that both EGTA and clodronate
prevent bisphosphonate-induced inhibition of Rap1A prenyla-
tion in J774 cells and osteoclasts. Our results extend those
observations to breast cancer cells.
From our data, it appears that calcium enhances the growth
inhibitory action of zoledronic acid as well as that of ibandro-
nate. As expected, the former bisphosphonate is more active
regardless of the calcium concentration, suggesting better cell
penetration or a stronger inhibition of farnesyl diphosphate
synthase (a key enzyme for protein prenylation). Of note, com-
plexes that form between different nitrogen-containing
bisphosphonates and calcium are characterized by the same
drug:calcium molar ratio (1:1.3) but exhibit different water
solubilities [27]. This suggests that the difference in potency
between bisphosphonates could be attributed partly to cellu-
lar drug pharmacokinetics.
Our observations are at variance with the findings of a recent
study [23], which showed that addition of 1 mmol/l calcium
partly reversed the growth inhibitory effect of zoledronic acid
on MDA-MB-231 cells, whereas it enhanced that of risedro-
nate. It must be noted, however, that in those experiments
MDA-MB-231 cells were cultured in serum-free Dulbecco's
modified Eagle's medium, which already contains 1.8 mmol/l
Figure 6
Effects of CaR agonist and antagonist on growth inhibition caused by ibandronate in cancer cells Effects of CaR agonist and antagonist on growth inhibition caused by ibandronate in cancer cells. MDA-MB-231 and MCF-7 cells were incubated 
for 72 hours with 30 μmol/l ibandronate (Iban) and/or calcium-sensing receptor (CaR) agonist in culture medium containing 0.6 mmol/l calcium, or 
with 30 μmol/l ibandronate and/or CaR antagonist in culture medium containing 1.6 mmol/l calcium. Cell culture densities were evaluated by crystal 
violet staining assay. Data are presented as percentages (mean ± standard deviation) of control values, which refer to culture with 0.6 mmol/l cal-
cium and without drugs. Mean of results pooled from two experiments (n = 12). *P < 0.01 versus control, analysis of variance, Dunnett post hoc test.Available online http://breast-cancer-research.com/content/10/1/R4
Page 9 of 11
(page number not for citation purposes)
calcium. Such experimental conditions are likely to obscure
the actual effect of calcium increase on bisphosphonate
activity.
In accordance with the findings of previous studies [4,5],
MDA-MB-231 cells proved to be less sensitive to the cytotoxic
action of bisphosphonates than other breast cancer cells. The
activation of the p38 mitogen-activated protein kinase path-
way by bisphosphonates in MDA-MB-231 cells has been
associated with increased cell survival and may account for a
relative resistance to these drugs [29]. In addition, MDA-MB-
213 cells might also differ in their ability to take up and/or
accumulate bisphosphonates. Indeed, our data show that
MCF-7 cells were more prone to accumulating [14C]ibandro-
nate than were MDA-MB-231 cells, suggesting that the differ-
ence in cell sensitivity to bisphosphonates may be related, at
least in part, to drug pharmacokinetics. Interestingly, our data
revealed that the cell sensitivity to ibandronate could be
associated with the ER status of the tumour cells. This could
be explained by the fact that oestrogen stimulation is critical
for survival in ER-positive breast tumour cells and that, as pre-
viously reported [7], the mitogenic effects of oestrogens are
completely abrogated by ibandronate. The clinical relevance of
this  in vitro observation should be further investigated to
establish whether ER status could be useful in predicting cell
responses to bisphosphonates.
Interestingly, unlike calcium, magnesium did not increase the
growth inhibition induced by ibandronate in breast cancer cell
lines. These data are in accordance with those reported in
macrophages and osteoclasts, showing that addition of 1
mmol/l magnesium did not increase the internalization of a flu-
orescent analogue of alendronate [12]. Although the bisphos-
phonates have almost the same affinity for calcium and
magnesium, the divalent cations may differ in their ability to
coordinate with bisphosphonates and to form multinuclear
complexes [25]. Indeed, magnesium demonstrates preference
for mononuclear complexes, whereas calcium tends to form
multinuclear species [30]. These data may account for the fact
that magnesium has little impact on bisphosphonate activity.
The CaR is expressed in MDA-MB-231 and MCF-7 cells [31].
In the present study its involvement in the effects of calcium
was examined by using a CaR agonist and a CaR antagonist.
As the results showed, these CaR modulators had no influ-
ence on ibandronate activity. These observations further
support the concept that enhanced cellular drug accumulation
resulting from calcium complexation is the major mechanism
that underlies calcium-induced potentiation of bisphospho-
nate antitumour activity.
Figure 7
Effect of calcium on [14C]ibandronate accumulation in MDA-MB-231  and MCF-7 cells Effect of calcium on [14C]ibandronate accumulation in MDA-MB-231 
and MCF-7 cells. Cells were exposed for 4 hours to 10 μmol/l 
[14C]ibandronate (102 mCi/mmol) in culture medium containing 0.6 or 
2.0 mmol/l calcium. The quantities of [14C]ibandronate associated with 
cell lysate supernatants were measured using a liquid scintillation coun-
ter. Results are presented as percentages (mean ± standard deviation) 
of control values, which refer to culture with 0.6 mmol/l calcium. Mean 
of results performed in triplicate. *P < 0.01 versus control, analysis of 
variance, Dunnett post hoc test.
Figure 8
Effect of calcium on ibandronate-induced inhibition of Rap1A prenyla- tion in MDA-MB-231 and MCF-7 cells Effect of calcium on ibandronate-induced inhibition of Rap1A prenyla-
tion in MDA-MB-231 and MCF-7 cells. Cells were incubated for 24 
hours with increasing concentrations of ibandronate (1 to 1,000 μmol/l) 
in culture medium containing 0.6 or 2.0 mmol/l calcium, lysed and sub-
jected to Western blot analysis. Equal amounts of proteins (25 μg) 
were subjected to 12% SDS-PAGE and electrotransferred onto nitro-
cellulose membranes. Immunodetection was performed with a goat pol-
yclonal anti-human antibody raised against the unprenylated form of 
Rap1A. Total Rap1 protein (input) was evaluated in parallel using a rab-
bit polyclonal anti-human Rap1 antibody. Representative data from two 
separate experiments.Breast Cancer Research    Vol 10 No 1    Journé et al.
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Conclusion
Our data indicate that extracellular calcium, at clinically rele-
vant concentrations, increases the cytotoxicity of ibandronate
by facilitating its accumulation by breast cancer cells. There-
fore, calcium released during the process of bone resorption
could enhance the antitumour effects of bisphosphonates and
contribute to their therapeutic activity.
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